Cargando…

Selenoprotein M stimulates the proliferative and metastatic capacities of renal cell carcinoma through activating the PI3K/AKT/mTOR pathway

High‐throughput sequencing methods have facilitated the identification of novel selenoproteins, which exert a vital role in the development and progression of tumor diseases. Recently, Selenoprotein M (SELM) is upregulated in several types of cancer. However, the biological roles of SELM in renal ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Hao, Shi, Qian‐Qian, Ge, Li‐Yuan, Zhuang, Qian‐Feng, Xue, Dong, Xu, Hai‐Yan, He, Xiao‐Zhou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Cancer Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712446/ https://www.ncbi.nlm.nih.gov/pubmed/31274247 http://dx.doi.org/10.1002/cam4.2403

Ejemplares similares

Asperolide A prevents bone metastatic breast cancer via the PI3K/AKT/mTOR/c‐Fos/NFATc1 signaling pathway
por: Jiang, Wenli, et al.
Publicado: (2020)

Ivermectin induces autophagy-mediated cell death through the AKT/mTOR signaling pathway in glioma cells
por: Liu, Jingjing, et al.
Publicado: (2019)

PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011)

Isorhamnetin inhibited the proliferation and metastasis of androgen-independent prostate cancer cells by targeting the mitochondrion-dependent intrinsic apoptotic and PI3K/Akt/mTOR pathway
por: Cai, Fangzhen, et al.
Publicado: (2020)

Array comparative genomic hybridization identifies high level of PI3K/Akt/mTOR pathway alterations in anal cancer recurrences
por: Cacheux, Wulfran, et al.
Publicado: (2018)

LncRNA‐LOC101928316 contributes to gastric cancer progression through regulating PI3K‐Akt‐mTOR signaling pathway
por: Li, Chengyun, et al.
Publicado: (2019)

Puerarin 6″‐O‐xyloside suppressed HCC via regulating proliferation, stemness, and apoptosis with inhibited PI3K/AKT/mTOR
por: Li, Long, et al.
Publicado: (2020)

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors
por: Wheler, Jennifer J., et al.
Publicado: (2016)

Targeting PI3K/Akt/mTOR Signaling in Cancer
por: Porta, Camillo, et al.
Publicado: (2014)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

Association of BAFF with PI3K/Akt/mTOR signaling in lupus nephritis
por: Ge, Fengmei, et al.
Publicado: (2017)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

LGR6 promotes the progression of gastric cancer through PI3K/AKT/mTOR pathway
por: Ke, Jing, et al.
Publicado: (2018)

mTOR up-regulation of SNRPA1 contributes to hepatocellular carcinoma development
por: Feng, Jing, et al.
Publicado: (2020)

The Paradox of Akt-mTOR Interactions
por: Vadlakonda, Lakshmipathi, et al.
Publicado: (2013)

Naringin inhibits colorectal cancer cell growth by repressing the PI3K/AKT/mTOR signaling pathway
por: Cheng, Hongyun, et al.
Publicado: (2020)

LncRNA GHET1 promotes cervical cancer progression through regulating AKT/mTOR and Wnt/β-catenin signaling pathways
por: Liu, Zhihui, et al.
Publicado: (2020)

Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia
por: Sacco, Antonio, et al.
Publicado: (2010)

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs
por: Markman, Ben, et al.
Publicado: (2010)

AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV
por: Bhatt, Aadra P., et al.
Publicado: (2013)

The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma
por: Matsuoka, Tasuku, et al.
Publicado: (2014)

Targeting the PI3K-AKT-mTOR signaling network in cancer
por: Khan, Khurum H., et al.
Publicado: (2013)

Outlook on PI3K/AKT/mTOR inhibition in acute leukemia
por: Fransecky, Lars, et al.
Publicado: (2015)

PI3K/AKT/mTOR pathway in pulmonary carcinoid tumours
por: Zhang, Zixuan, et al.
Publicado: (2017)

Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
por: Sun, Eun Jin, et al.
Publicado: (2021)

PI3K/AKT/mTOR pathway in tumor progression of oligodendrogliomas
por: Lisi, Lucia
Publicado: (2020)

Roles of PI3K/AKT/mTOR Axis in Arteriovenous Fistula
por: Ratti, Stefano, et al.
Publicado: (2022)

PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
por: Zhu, Kunrui, et al.
Publicado: (2022)

Comprehensive analysis of the effect of rs2295080 and rs2536 polymorphisms within the mTOR gene on cancer risk
por: Qi, Guang-Hui, et al.
Publicado: (2020)

MicroRNA‐221 promotes breast cancer resistance to adriamycin via modulation of PTEN/Akt/mTOR signaling
por: Yin, Yingchun, et al.
Publicado: (2020)

ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer
por: Farmaki, Elena, et al.
Publicado: (2023)

Combination of aloin and metformin enhances the antitumor effect by inhibiting the growth and invasion and inducing apoptosis and autophagy in hepatocellular carcinoma through PI3K/AKT/mTOR pathway
por: Sun, Ruijie, et al.
Publicado: (2019)

miR-152/TNS1 axis inhibits non-small cell lung cancer progression through Akt/mTOR/RhoA pathway
por: Duan, Jinjin, et al.
Publicado: (2021)

Metformin induces degradation of mTOR protein in breast cancer cells
por: Alalem, Mohamed, et al.
Publicado: (2016)

Control of mTOR Signaling by Ubiquitin
por: Jiang, Yao, et al.
Publicado: (2019)

The PI3K/Akt/mTOR pathway is involved in CVB3-induced autophagy of HeLa cells
por: Chang, Huan, et al.
Publicado: (2017)

The PI3K/AKT/mTOR Signaling Pathway Is Overactivated in Primary Aldosteronism
por: Su, Hengchuan, et al.
Publicado: (2013)

Therapeutic targets for cancer: Current concepts with PI 3-K, Akt, & mTOR
por: Maiese, Kenneth
Publicado: (2013)

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
por: Li, Xiaoman, et al.
Publicado: (2016)

Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis
por: Reilly, R., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_p81j5kl2p8oct6nma73i29u1es